FDA panel backs J&J's new-class antidepressant - PMLiVE

FDA panel backs J&J's new-class antidepressant  PMLiVEJohnson & Johnson could be just weeks away from approval of the first new drug class for depression in decades, giving a new option for patients with severe, ...